Meanwhile, PLX4032 from Roche and Plexxikon works via a different mechanism and shrinks tumors in a mind-boggling 80% of melanoma patients whose tumors have a mutation called in a gene called BRAF, These results were published this week in the New England Journal of Medicine.

FORBES: The Cancer Trial Bristol and Roche Must Do Now